دورية أكاديمية
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
| العنوان: | Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial |
|---|---|
| المؤلفون: | Trotman, Judith, Barrington, Sally F, Belada, David, Meignan, Michel, MacEwan, Robert, Owen, Carolyn, Ptáčník, Václav, Rosta, András, Fingerle-Rowson, Günter R, Zhu, Jiawen, Nielsen, Tina, Sahin, Deniz, Hiddemann, Wolfgang, Marcus, Robert E, Davies, Andrew, Hertzberg, Mark, Grigg, Andrew, Cannell, Paul, Quach, Hang, Opat, Stephen, Tam, Constantine, Marlton, Paula, Janssens, Ann, Offner, Fritz, Van eygen, Koen, Sangha, Randeep, Mckay, Pam, Wilson, Jonathan, Van Der Jagt, Richard, Roitman, Daryl, Trneny, Marek, Mayer, Jiri, Le Du, Katell, Solal-Celigny, Philippe, Cartron, Guillaume, Foussard, Charles, Frickhofen, Norbert, Schmidt, Peter, Graeven, Ullrich, Gaska, Tobias, Schlag, Rudolf, Sökler, Martin, Prange-Krex, Gabriele, Florschütz, Axel, Lindemann, Hans-Walter, Schimmelpfennig, Christoph, Tonndorf, Solveig, Hänel, Mathias, Hess, Georg, Schalk, Enrico, Hütten, Heiko, Doelken, Gottfried, Pfreundschuh, Michael, Keller, Ulrich, Herold, Michael, Forstpointner, Roswitha, Vehling-Kaiser, Ursula, Hoffmann, Martin, Borbenyi, Zita, Udvardy, Miklos, Demeter, Judit, Rambaldi, Alessandro, Morra, Enrica, Massimo, Federico, Majolino, Ignazio, Balzarotti, Monica, Semenzato, Gianpietro, Canales Albendea, Miguel Angel, Peñalver Parraga, Francisco Javier, Soler Campos, Alfonso, Sancho Cia, Juan Manuel, Marquez Navarro, Jose Antonio, Grande Garcia, Carlos, Nilsson-Ehle, Herman, Mccarthy, Helen, Pocock, Chris, Sadullah, Shalal, Malladi, Ram, Radford, John, Kanfer, Ed, Kruger, Anton, Culligan, Dominic, Dyer, Martin, Pettengell, Ruth, Seymour, John, Gribben, John, Al-Ismail, Saad, Al-Refaie, Faris, Blesing, Norbert, Macnamara, Christopher, O'callaghan, Ann, Haynes, Andrew, Follows, George, Johnson, Roderick, Cunningham, David, Bowles, Kristian, Collins, Graham, Gallop-Evans, Eve, Robinson, Stephen, Subash, Chezhian, Bailey, James, Holden, Viran, Neidhart, Jeffrey, De Oliveira, Moacyr, Tezcan, Haluk, Kim, Kevin, Kambhampati, Suman, Lanier, Keith, Mcclean, John, Tobinai, Kensei, Hatake, Kiyohiko, Ogura, Michinori, Uchida, Toshiki, Ando, Kiyoshi, Kinoshita, Tomohiro, Höhler, Thomas, Stauder, Heribert, Kirsch, Andreas, Koenigsmann, Michael, Kremers, Stephan, Illmer, Thomas, Witzens-Harig, Mathias, La Roseé, Paul, Dürig, Jan, Kneba, Michael, Hensel, Manfred, Fuxius, Stefan, Bergmann, Lothar, Hübel, Kai, Buske, Christian, Marks, Reinhard, Wulf, Gerald, Lerchenmueller, Christian, Schmits, Rudolf, Reinwald, Mark, Lengfelder, Eva, Scott, Fiona, Chou, Takaaki, Taniwaki, Masafumi, Yoshida, Isao, Ishizawa, Kenichi, Uike, Naokuni, Uoshima, Nobuhiko, Kamitsuji, Yuri, Iida, Shinsuke, Ohmine, Ken, Nosaka, Kisato, Ide, Kazuhiko, Ishikawa, Takayuki, Desjardins, Pierre, Finn, Nicholas, Zhu, Jun, Li, Wei, Yu, Li, Ren, Hanyun, Shi, Yuan Kai, Wu, Gang, Hong, Xiaonan, Zhang, Qingyuan, Feng, Jifeng, Zhan, Rong, Lin, Tongyu, Leppa, Sirpa, Costello, Regis, Tempescul, Adrian, Sanhes, Laurence, Tournilhac, Olivier, Kirchen, Heinz, Hebart, Holger, Weide, Rudolf, Jentsch-Ullrich, Kathleen, Avivi, Irit, Nagler, Arnon, Gurion, Ronit, Shpilberg, Ofer, Leoni, Pietro, Baldini, Luca, Samoylova, Olga, Myasnikov, Alexandr, Tan, Tran-Der, Chang, Hung, Kumagai, Kyoya, Tsukamoto, Norifumi, Tsukasaki, Kunihiro, Beatty, Patrick, Usui, Noriko, Izutsu, Koji, Murayama, Tohru, Ichinohe, Tatsuo, Kubo, Kohmei, Ishida, Fumihiro, Beck, J. Thaddeus, Griesinger, Frank, Osmanov, Dzhelil, Dakhil, Shaker, Clavert, Aline, Maruyama, Dai, Terui, Yasuhito, Yamamoto, Kazuhito, Eigendorff, Ekkehard, Kobayashi, Tsutomu, Ichikawa, Satoshi, Choi, Ilseung, Wada, Katsuya, Kikukawa, Yoshitaka, Matsuoka, Masao, Yoshino, Takayuki, Minami, Yosuke |
| المساهمون: | J. Trotman, S.F. Barrington, D. Belada, M. Meignan, R. MacEwan, C. Owen, V. Ptáčník, A. Rosta, G.R. Fingerle-Rowson, J. Zhu, T. Nielsen, D. Sahin, W. Hiddemann, R.E. Marcu, A. Davie, M. Hertzberg, A. Grigg, P. Cannell, H. Quach, S. Opat, C. Tam, P. Marlton, A. Janssen, F. Offner, K. Van eygen, R. Sangha, P. Mckay, J. Wilson, R. Van Der Jagt, D. Roitman, M. Trneny, J. Mayer, K. Le Du, P. Solal-Celigny, G. Cartron, C. Foussard, N. Frickhofen, P. Schmidt, U. Graeven, T. Gaska, R. Schlag, M. Sökler, G. Prange-Krex, A. Florschütz, H. Lindemann, C. Schimmelpfennig, S. Tonndorf, M. Hänel, G. He, E. Schalk, H. Hütten, G. Doelken, M. Pfreundschuh, U. Keller, M. Herold, R. Forstpointner, U. Vehling-Kaiser, M. Hoffmann, Z. Borbenyi, M. Udvardy, J. Demeter, A. Rambaldi, E. Morra, F. Massimo, I. Majolino, M. Balzarotti, G. Semenzato, M.A. Canales Albendea, F.J. Peñalver Parraga, A. Soler Campo, J.M. Sancho Cia, J.A. Marquez Navarro, C. Grande Garcia, H. Nilsson-Ehle, H. Mccarthy, C. Pocock, S. Sadullah, R. Malladi, J. Radford, E. Kanfer, A. Kruger, D. Culligan, M. Dyer, R. Pettengell, J. Seymour, J. Gribben, S. Al-Ismail, F. Al-Refaie, N. Blesing, C. Macnamara, A. O'callaghan, A. Hayne, G. Follow, R. Johnson, D. Cunningham, K. Bowle, G. Collin, E. Gallop-Evan, S. Robinson, C. Subash |
| بيانات النشر: | Lancet Publishing Group |
| سنة النشر: | 2018 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | Settore MED/15 - Malattie del Sangue |
| الوصف: | Background: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET–CT responses after first-line immunochemotherapy in the GALLIUM study. Methods: GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1–3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment. Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m2 on day 1 of each cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone (known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral administration), or six 28-day cycles with bendamustine, followed by maintenance antibody every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed progression-free survival, has been reported previously. This secondary analysis reports PET and CT-based responses at end-of-induction therapy and explains their relation with progression-free and overall survival outcomes in patients with available scans. As per protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with available PET facilities, and optional thereafter), acquired at baseline and end of induction (PET population), were assessed prospectively by investigators and an independent review committee (IRC) applying International Harmonisation Project (IHP) 2007 response criteria, and retrospectively by the IRC only ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/30309758; info:eu-repo/semantics/altIdentifier/wos/WOS:000449100300049; volume:19; issue:11; firstpage:1530; lastpage:1542; numberofpages:13; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/2434/600079Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85057171802 |
| DOI: | 10.1016/S1470-2045(18)30618-1 |
| الإتاحة: | https://doi.org/10.1016/S1470-2045Test(18)30618-1 http://hdl.handle.net/2434/600079Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.F5766802 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S1470-2045(18)30618-1 |
|---|